Previous 10 | Next 10 |
home / stock / esalf / esalf news
TOKYO, Mar 23, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch "NouKNOWTM" (pronounced "NOH-NOH"), a new digital tool (non-medical device) for self-assessment of brain performance (brain health). The tool was developed by Eisai using the cognitive function test "Cog...
TOKYO, Mar 19, 2020 - (JCN Newswire) - EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has given notification of the results of reexamination to the effect that the "all-case surveillance" specified drug use-result...
Institutional investors rushed to acquire shares of cancer drug developer Epizyme (NASDAQ: EPZM) in advance of a catalyst-rich 2020. Those who acted were not disappointed. In January, the Food and Drug Administration (FDA) granted accelerated approval for the company's targeted cancer drug, ...
TOKYO, Feb 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by FUJI YAKUHIN, for development and distribution in China. Bas...
For its Contributions Towards Patients With Liver Disease Through the Eisai-Originated Orally Available Kinase Inhibitor Lenvima TOKYO, Feb 21, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it received the President's Award at the 8th Technology Management and Innovation Award...
The Food and Drug Administration has asked Tokyo-based Eisai (OTC: ESALF) to withdraw its weight-loss drugs Belviq and the extended release formulation, Belviq XR, from the U.S. market. The Japanese drugmaker reluctantly complied, submitting a request to voluntarily withdraw the drug. When ...
For the past several years, a clinical trial from Washington University (St. Louis) has been underway in people with genetic mutations that lead to early-onset Alzheimer's. The Dominantly Inherited Alzheimer's Network (Trials Unit), DIAN-TU, has been dosing 194 such patients with one of two ...
Eisai Co., Ltd. (ESALF) Q4 2019 Earnings Conference Call January 31, 2020 2:30 AM ET Company Participants Ryohei Yanagi - Executive Vice President, CFO and Chief IR Ivan Cheung - Senior Vice President and President, Neurology Business Group Terushige Iike - Senior Vice President ...
Biogen ( BIIB ) and Neurotrope ( NTRP ) are two companies frantically trying to save their Alzheimer’s drugs - aducanumab and bryostatin-1 - from lackluster data. One is at the top of the pharmaceutical heap and the other is near the bottom. Both are led by scientists who are certain ...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...